Treatment approaches of gastrointestinal dysfunction in Parkinson's disease, therapeutical options and future perspectives

被引：15
|
作者：
Woitalla, D. [1 ]
Goetze, O. [2 ]
机构：
[1] Ruhr Univ Bochum, Dept Neurol, St Josef Hosp, D-44791 Bochum, Germany
[2] Univ Zurich Hosp, Div Gastroenterol & Hepatol, Zurich, Switzerland
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2011年 / 310卷 / 1-2期
关键词：
Gastrointestinal dysfunction; Treatment options; Enteric nervous system; Gastroparesis; Parkinson's disease; ENTERIC NERVOUS-SYSTEM; PLACEBO-CONTROLLED TRIAL; FUNCTIONAL DYSPEPSIA; LEWY BODIES; RESPONSE FLUCTUATIONS; CHRONIC CONSTIPATION; HEALTHY-VOLUNTEERS; NONMOTOR SYMPTOMS; GASTRIC-MOTILITY; 5-HT4; AGONIST;
D O I：
10.1016/j.jns.2011.06.050
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Gastrointestinal (GI) dysfunction is a common but underestimated feature in Parkinson's disease (PD). Out of the multimodal spectrum of treatment options, there currently are only a few pharmacological treatments available to improve gastrointestinal motility and symptoms. Because enteric nervous function is mainly regulated by transmitters different from those involved in the brain, dopamine replacement is not a treatment option in PD patients. This article focuses on the known regulative mechanism of Cl function and presents known and upcoming treatment options for GI dysfunction in PD. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码：152 / 158
页数：7
相关论文
共 50 条
12345